Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pain Symptom Manage. 1994 Feb;9(2):119-21.

Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: a preliminary report.

Author information

1
Pain Therapy and Palliative Care Division, National Cancer Institute, Milan, Italy.

Abstract

We evaluated the local and systemic tolerability of ketorolac administered through continuous subcutaneous infusion in ten cancer patients. The patients were monitored daily for the severity and duration of pain, and the development of other symptoms. The duration of injection site varied from 1 to more than 7 days. No patients complained of local discomfort or pain. Mild local bleeding at the site of drug injection was observed in seven cases. No increase in the intensity of symptoms was observed during the infusion of ketorolac.

PMID:
8021534
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center